Does metformin decrease blood pressure in patients with Type 2 diabetes intensively treated with insulin?

被引:20
|
作者
Wulffelé, MG
Kooy, A
Lehert, P
Bets, D
Donker, AJM
Stehouwer, CDA
机构
[1] Bethesda Gen Hosp, Dept Internal Med, NL-7909 AA Hoogeveen, Netherlands
[2] FUCAM, Dept Stat, Fac Econ, Mons, Belgium
[3] E Merck Nederland BV, Clin Res & Dev, Amsterdam, Netherlands
[4] Vrije Univ Amsterdam Med Ctr, Dept Internal Med, Amsterdam, Netherlands
[5] Vrije Univ Amsterdam Med Ctr, Inst Cardiovasc Res, Amsterdam, Netherlands
[6] Univ Hosp Maastricht, Dept Med, Maastricht, Netherlands
关键词
blood pressure; metformin; randomized controlled trial; Type; 2; diabetes; 24-h ambulatory blood pressure monitoring;
D O I
10.1111/j.1464-5491.2005.01554.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims We investigated in a double-blind study whether metformin reduces blood pressure (BP) in patients with Type 2 diabetes intensively treated with insulin. Methhods A total of 220 patients with Type 2 diabetes were asked to undergo 24-h ambulatory BP monitoring (24-h ABPM). One hundred and eighty-two gave informed consent. Eighty-nine were randomized to metformin and 93 to placebo. Thirty-five subjects dropped out (13 placebo, 22 metformin users); 147 patients underwent a second 24-h ABPM, 16 weeks after randomization. Results Systolic BP (SBP), diastolic BP (DBP), pulse BP (PP), mean BP (MP) and heart rate (HR) were measured as office BP measurements and as 24-h ABPM for 24-h, day and night. Office BP measurements did not differ significantly between the placebo- and metformin-treated groups for any BP measure, but showed a non-significant trend for SBP reduction with metformin use (mean baseline-adjusted difference, metformin minus placebo: -4.2 mmHg, 95% CI, -9.9 to +1.5; P = 0.15). The baseline-adjusted differences of the ambulatory measurements were -0.2 mmHg (95% CI, -2.9 to +2.6) for the 24-h SBP, and +1.1 mmHg (95% CI, -0.7 to +2.8) for the 24-h DBP. On the whole, BP differences between metformin- and placebo-treated groups were not statistically significant. The only significant difference was for night-time PP (baseline-adjusted difference: -2.2 mmHg; 95% CI, -4.2 to -0.2). These results were not different after adjustment for age and diabetes duration, or for (changes in) body mass index, glycated haemoglobin, insulin dose or plasma homocysteine. Conclusion Metformin does not significantly affect BP in patients with Type 2 diabetes intensively treated with insulin.
引用
收藏
页码:907 / 913
页数:7
相关论文
共 50 条
  • [21] Blood Pressure Management in Patients with Type 2 Diabetes
    Eguchi, Kazuo
    INTERNAL MEDICINE, 2015, 54 (18) : 2285 - 2289
  • [22] Progression to insulin therapy among patients with type 2 diabetes treated with sitagliptin or sulphonylurea plus metformin dual therapy
    Inzucchi, S. E.
    Tunceli, K.
    Qiu, Y.
    Rajpathak, S.
    Brodovicz, K. G.
    Engel, S. S.
    Mavros, P.
    Radican, L.
    Brudi, P.
    Li, Z.
    Fan, C. P. S.
    Hanna, B.
    Tang, J.
    Blonde, L.
    DIABETES OBESITY & METABOLISM, 2015, 17 (10) : 956 - 964
  • [23] Metformin and -cell function in insulin-treated patients with type 2 diabetes: A randomized placebo-controlled 4.3-year trial
    Top, Wiebe
    Stehouwer, Coen
    Lehert, Philippe
    Kooy, Adriaan
    DIABETES OBESITY & METABOLISM, 2018, 20 (03) : 730 - 733
  • [24] Insulin resistance, not diabetes status, determines blood pressure in obese and type 2 diabetic patients
    Lewanczuk, RZ
    Paty, BW
    Toth, EL
    AMERICAN JOURNAL OF HYPERTENSION, 2004, 17 (05) : 32A - 32A
  • [25] EFFECTS OF VITAGLIPTIN COMBINED WITH METFORMIN ON GLUCOSE METABOLISM, INSULIN RESISTANCE, AND HEMORHEOLOGY IN PATIENTS WITH TYPE 2 DIABETES
    Chen, Tielin
    Wang, Shuguang
    Yu, Jiangsu
    ACTA MEDICA MEDITERRANEA, 2021, 37 (02): : 795 - 799
  • [26] The contribution of metformin to glycaemic control in patients with Type 2 diabetes mellitus receiving combination therapy with insulin
    Tong, PC
    Chow, CC
    Jorgensen, LN
    Cockram, CS
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2002, 57 (02) : 93 - 98
  • [27] Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes
    Jones, TA
    Sautter, M
    Van Gaal, LF
    Jones, NP
    DIABETES OBESITY & METABOLISM, 2003, 5 (03) : 163 - 170
  • [28] Efficacy of Combination of Insulin Glargine with either Metformin or Sulfonylurea in Patients with Poorly Controlled Type 2 Diabetes
    Chuang, Shih-Ming
    Wang, Chao-Hung
    Liu, Sung-Chen
    Chien, Ming-Nan
    Chen, Wei-Che
    INTERNATIONAL JOURNAL OF GERONTOLOGY, 2020, 14 (02) : 138 - 141
  • [29] Observational Study of Patients in Morocco With Uncontrolled Type 2 Diabetes Treated With Metformin and/or Sulfonylurea With or Without Insulin
    El Ansari, Nawal
    Chadli, Asmae
    El Aziz, Siham
    El Mghari, Ghizlane
    El Achhab, Youness
    Seqat, Mehdi
    Nejjari, Chakib
    JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2015, 5 (06) : 321 - 327
  • [30] Metformin-treated patients with type 2 diabetes have normal mitochondrial complex I respiration
    Larsen, S.
    Rabol, R.
    Hansen, C. N.
    Madsbad, S.
    Helge, J. W.
    Dela, F.
    DIABETOLOGIA, 2012, 55 (02) : 443 - 449